Tag Archives: finance

RESI London Innovator’s Pitch Challenge Finalists 

18 Nov

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The Innovator’s Pitch Challenge showcases early-stage companies developing breakthrough technologies across key sectors of life sciences.

The Innovator’s Pitch Challenge (IPC) returns to RESI London with a full lineup of pioneering startups presenting across multiple themed sessions. Each finalist will pitch to panels of relevant investors and industry leaders, gaining practical feedback and creating valuable connections with partners actively seeking new technologies. The IPC provides fundraising companies with a platform to elevate their visibility and engage with a global network of investors and strategics.

If you are attending RESI London, make time to see these pitches and meet the founders throughout the day. Delegates participating in partnering can also schedule one-on-one meetings with the finalists. Full event and registration details are available at resiconference.com/resi-london.

Meet the RESI London Innovator’s Pitch Challenge Finalists

Session 1 | 9:00 – 10:00 AM | Therapeutics

Session 2 | 10:00 – 11:00 AM | Diagnostics Tools & Platforms

Session 3 | 11:00 AM – 12:00 PM | Therapeutics

Session 4 | 1:00 – 2:00 PM | Therapeutics & Medical Devices

Session 5 | 2:00 – 3:00 PM | Therapeutics

Session 6 | 3:00 – 4:00 PM | Medical Devices

Session 7 | 4:00 – 5:00 PM | R&D and Enabling Technologies
Register for RESI London

Tags: , , , , , , , , , , , ,

Discover Early-Stage Life Science Opportunities at London Bio-Innovation Week

18 Nov

By Greg Mannix, VP, EMEA Business Development, LSN

Educational sessions, networking, and investor partnering, December 2–5, 2025 

London Bio-Innovation Week brings together the global life science community for a series of premier events focused on early-stage innovation, taking place December 2–5, 2025. The week offers a unique combination of educational programming, networking opportunities, and investor partnering across multiple sectors of the life sciences. 

Participating events include RESI London by Life Science Nation, Genesis Conference by One Nucleus, the SLAS–ELRIG Meet-up, Advanced Therapies Integrates by LSI, and several free educational programs. Together, these events create an ecosystem where scientists, entrepreneurs, investors, and industry dealmakers can connect and collaborate. 

Opportunities at London Bio-Innovation Week include: 

  • Scientists engage with those commercializing innovations. 
  • Investors and industry dealmakers are discovering the next breakthroughs. 
  • Early-stage investors meet entrepreneurs seeking capital. 
  • Life science dealmakers are gaining early access to cutting-edge technologies. 
  • Building meaningful connections across the life science ecosystem. 

Join us for our upcoming webinar, that will provide an overview of London Bio-Innovation Week, highlighting how the events can help advance your company, discover investment opportunities, and connect with key partners. 

Webinar Speakers: 

  • Sougato Das, President & COO, Life Science Nation 
  • Tony Jones, Chief Executive Officer, One Nucleus 
  • Vicki Loise, Chief Executive Officer, SLAS (Society for Laboratory Automation and Screening) 
  • Sanj Kumar, Chief Executive Officer, ELRIG 

Webinar Details: 

  • Date & Time: November 20, 2025, 9:00 AM Eastern Time (US & Canada) 

Register RESI London now to explore all the ways London Bio-Innovation Week can support your early-stage life science goals and connect you with the right partners. 

Register for RESI London

Tags: , , , , ,

Hot Investor Mandate: Family Office Backed Venture Fund Invests in Pre-Clinical Therapeutic Platforms Across the Globe

18 Nov

This early-stage venture fund, with offices in Western Europe, is led by a team with deep expertise across venture funding, company building, and therapeutic development. The firm is currently focused on cell and gene therapy, with particular interest in the manufacturing technologies that support these modalities. 

The firm is especially interested in therapeutic platforms at the pre-clinical stage, including cutting-edge cell therapies for regenerative medicine and autoimmune conditions that require localized manufacturing capabilities. It seeks to support breakthrough technologies at the seed stage. 

The firm typically takes an active role in its portfolio companies, frequently leading rounds, providing strategic guidance, and ensuring board-level engagement, either by taking a board seat directly or placing a qualified expert. In addition to company creation, the firm also invests in existing ventures, often syndicating with other institutional investors to support early-stage growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: VC Firm Invests in Drug Discovery Enabling Tools, Techbio, AI-Driven Applications Globally With a Focus on USA-Based Companies  

18 Nov

A pharma-tech focused venture capital firm, founded in 2022 and headquartered in the US, invests in early-stage companies and also has the capability to incubate new ventures. The firm is driven by the belief that the pharmaceutical industry represents a strong and scalable customer base, and seeks technologies that align with or enhance the pharma value chain. While open to global opportunities, the firm shows a preference for companies based in the United States. Typical investment sizes range from $2 million to $5 million, and the firm is flexible in its role, able to lead or follow in financing rounds. 

The firm invests across a broad spectrum of pharma-tech, including technologies targeting patients or providers, tech-bio platforms, drug discovery tools, AI-driven applications, supply chain innovations, and data-centric platforms. In essence, it is interested in any innovation that contributes to the pharmaceutical and life sciences value chain. The firm is disease-agnostic in its approach. 

An active investor, the firm typically takes a board seat or observer role and prefers companies that have pharmaceutical companies as at least one major customer or are built with pharma as the primary target market. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: USA-Based VC Firm Seeks Longevity-Focused Investments, Engaging in Seed to Series A Rounds

18 Nov

A venture capital firm based in the US is focused on incubating and investing in longevity-focused companies that aim to improve quality of life for older adults. The firm primarily invests at the Seed and Series A stages, with typical initial check sizes ranging from $100,000 to $500,000. The investment focus is on opportunities based in the United States. 

The firm invests broadly across the life sciences and healthcare sectors, provided there is a clear connection to aging and longevity. Areas of interest include healthcare quality and cost, care capacity, healthcare benefits activation, aging in place, and financial longevity. The firm has made investments in medical devices, diagnostics, and digital health companies, and currently maintains an active portfolio of more than 15 companies. It generally does not invest in biotech. The firm is open to backing companies at the earliest stages of development. 

There are no specific requirements regarding company structure or founding team experience. The firm is flexible in its role and may choose to lead or co-invest depending on the opportunity. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Late-Stage Venture & Growth Equity Investor Backing De-Risked Therapeutics and Medical Device Opportunities

18 Nov

A venture capital and private equity firm focuses on investments in the life sciences sector, with a primary emphasis on pharmaceuticals and therapeutics, and a secondary interest in medical devices. The firm invests from Series A through growth-stage transactions and is currently deploying capital from its third fund. Typical investment sizes range from $10 million to $40 million. 

The firm prioritizes opportunities with a de-risked clinical development pathway, such as those involving repurposed or reformulated drugs, established mechanisms of action, 505(b)(2) regulatory strategies, or programs with proof-of-concept clinical data. For therapeutic assets, the firm primarily targets clinical-stage companies, ideally with completed Phase I trials. For medical devices, the firm considers clinical-stage opportunities with a clear regulatory and commercialization path. The firm is indication-agnostic but maintains a strong interest in 505(b)(2) products.  
 
The firm seeks companies with a clearly defined path to regulatory approval, supported by robust intellectual property and market exclusivity. It plays an active role in its portfolio companies and takes a board seat in every investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

From Lab to Market: Why Life Science Companies Are Drawn to Singapore 

12 Nov

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

LSN is proud to announce our partnership with Enterprise SG for RESI JPM 2026, to foster meaningful conversations on global life science innovation, investment and cross-border collaboration. Learn how Singapore is a dynamic launchpad for innovation and home to cutting-edge startups ready to collaborate on your next breakthrough. Join us at our upcoming panel on January 12 to find out more! 

As global healthcare challenges intensify, innovative biomedical technologies from Asia are stepping up to drive change, translating life science research into real-world solutions. Increasingly, investors, corporates, startups, and healthcare systems around the world are seeing the urgency in bridging the East and West to improve healthcare outcomes and deliver value-based care.

Singapore, located at the heart of Asia, is a dynamic hub for biomedical innovation, driven by a strong network of global investors, researchers, mentors, and innovators. With decades of sustained government investments and a robust talent pipeline from world-class universities and research institutes, it is home to over 500 biomedical and medtech companies. The ecosystem has attracted venture capitalists and venture builders like MPM BioImpact, Polaris Partners, and Flagship Pioneering, as well as global pharma leaders such as Pfizer, Roche, and Johnson & Johnson. These players work closely with government agencies, like Enterprise Singapore, that drive startup development, provide patient funding, expertise, infrastructure, and networks crucial for producing globally competitive solutions.

Singapore’s strategic position as a bridge between Asian and global markets enables it to play an outsized role in driving biomedical advancements. This works both ways, as a gateway for global companies to access the growing opportunities in Asia, and as a springboard for regional companies to expand worldwide. For example, through partnerships with healthcare organisations like Cedars-Sinai and Mayo Clinic in the US, Enterprise Singapore supports Singapore startups to test and scale their solutions in overseas markets, facilitating a bi-directional flow of innovation to improve healthcare for communities.

Join Enterprise Singapore at the ‘Asia Cross Border Investments Panel’ to explore how cross-border capital, talent, and technologies are converging to drive breakthroughs in precision medicine, innovative therapies, and next-generation diagnostics. The panel will take place on January 12, 2026, from 11:00 am to 12:00 pm at RESI JPM by LSN, held at the Marriott Marquis, San Francisco. Learn from prominent industry leaders how transcontinental partnerships, including those with Singapore, are shaping the future of healthcare innovation – from discovery to global commercialisation.

To join the conversation, please contact Claire Jeong, VP of Investor Research, Asia BD, at c.jeong@lifesciencenation.com.

Tags: , , , , , , , , , , ,

← Older Entries
Newer Entries →